The present invention is drawn to artificial metalloenzymes for use in cyclopropanation reactions, amination and C—H insertion.

The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

The present invention encompasses compounds of formula (I) wherein the groups R.sup.1 to R.sup.3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

##STR00001##

The present invention encompasses compounds of formula (I) wherein the groups R.sup.1 to R.sup.3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

##STR00001##

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer includes, as a first host material, a first compound that includes at least one group represented by a formula (11) below, the first compound being represented by a formula (1) below, the second emitting layer includes a second compound represented by a formula (2) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer. L.sub.101 is a single bond or a substituted or unsubstituted arylene group having 6 to 50 ring carbon atoms. Ar.sub.101 is a substituted or unsubstituted aryl group having 6 to 50 ring carbon atoms. mx is 0, 1, 2, 3, 4, or 5.

##STR00001##

The present invention provides a solid color film, a preparation method thereof and a display device. The solid color film includes a transparent substrate and a solid color material dispersed in the transparent substrate, and the solid color material includes a host structure formed of cucurbituril and a guest structure supported on the host structure and formed by bonding a carboxyl group-containing rhodamine-based dye and an aminoadamantane through a chemical bond, wherein the guest structure is bonded to the host structure through the adamantane to form a host-guest structure.

The present invention provides a solid color film, a preparation method thereof and a display device. The solid color film includes a transparent substrate and a solid color material dispersed in the transparent substrate, and the solid color material includes a host structure formed of cucurbituril and a guest structure supported on the host structure and formed by bonding a carboxyl group-containing rhodamine-based dye and an aminoadamantane through a chemical bond, wherein the guest structure is bonded to the host structure through the adamantane to form a host-guest structure.

The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof.

This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light.

The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.

The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof.

This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light.

The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.